Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha TeknovaTKNO +0.56%63 Days Payable is 18.74 as of Mar. 2026, which is 31% below its 10-year median of 27.26. GuruFocus rates TKNO with a GF Score™ of 63/100 and a GF Value™ of $3.55 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 925 Drug Manufacturers companies, Alpha Teknova ranks worse than 96.65% on this metric.
The historical rank and industry rank for Alpha Teknova's Days Payable or its related term are showing as below:
TKNO'
s Days Payable Range Over the Past 10 Years
Min: 13.86 Med: 27.26 Max: 36.77
Current: 18.1
During the past 7 years, Alpha Teknova's highest Days Payable was 36.77. The lowest was 13.86. And the median was 27.26.
TKNO's Days Payable is ranked worse than 96.65% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs TKNO: 18.10
Alpha Teknova's Days Payable
increased
from Mar. 2025 (16.00) to Mar. 2026 (18.74).
It may suggest that Alpha Teknovadelayed paying its suppliers.
Alpha Teknova Days Payable Related Terms
Alpha Teknova Days Payable Historical Data
* Premium members only.
The historical data trend for Alpha Teknova's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alpha Teknova's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Teknova Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpha Teknova's Days Payable distribution charts can be found below:
* The bar in red indicates where Alpha Teknova's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Alpha Teknova's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Teknova (TKNO) has a Days Payable of 18.74 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alpha Teknova and its competitors. This is 31% below median its historical median of 27.26. Over the past decade, Alpha Teknova's Days Payable has ranged from 13.86 to 36.77. According to the industry distribution chart, Alpha Teknova ranks #894 out of 925 companies in the Drug Manufacturers industry, placing it in the top 96.6%.
Is Alpha Teknova's Days Payable too high?
Alpha Teknova's current Days Payable of 18.74 is 31% below median its 10-year median of 27.26. Over the past 10 years, this metric has ranged from a low of 13.86 to a high of 36.77. The Drug Manufacturers industry median Days Payable is 90.38. Alpha Teknova's value of 18.74 is 79.3% below this industry median. Based on the distribution chart, Alpha Teknova ranks #894 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alpha Teknova has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's Days Payable compare to AKBA and ORGO?
According to the Drug Manufacturers industry distribution chart, Alpha Teknova ranks #894 out of 925 companies for Days Payable. This places Alpha Teknova in the lower half of its industry. The industry median Days Payable is 90.38. Alpha Teknova's value of 18.74 is 79.3% below this benchmark. Historically, Alpha Teknova's own Days Payable has ranged from 13.86 to 36.77 over the past decade. While the company's 10-year median is 27.26 vs. the industry median of 90.38, Alpha Teknova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Teknova's current Days Payable of 18.74 is 79.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Alpha Teknova and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current Days Payable is 18.74, which is 31% below median its own 10-year median of 27.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.55, compared to a current price of $5.34 — trading 50.4% above its estimated fair value. The current Days Payable is 18.74, which is 31% below median its 10-year median of 27.26 and 79.3% below the Drug Manufacturers industry median of 90.38. Alpha Teknova's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current Days Payable is 18.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $5.34 is trading 50.4% above its estimated GF Value™ of $3.55.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
Days Payable: 18.74 (31% below median its 10-year median of 27.26)
GF Value™: $3.55 vs. price of $5.34 (50.4% above fair value)
Industry Position: 79.3% below the Drug Manufacturers median (#894 of 925)
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
63GF Score
Get the complete analysis for TKNO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
